MARKET WIREReuters • 1h ago
Oil slips more than 1% as talks continue on ending Iran war - ReutersOil slips more than 1% as talks continue on ending Iran war Reuters
Why ZJYL Stock dropped -2.10% Today — RQD Quant Desk Flash
$1.86 -2.10% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.85
JIN MEDICAL INTERNATIONAL LTD. (Class A) (ZJYL) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $294.2M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ZJYL Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ZJYL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-01, JIN MEDICAL INTERNATIONAL LTD. (Class A) (NASDAQ: ZJYL) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $1.86 (-2.10% 1D, market cap $294.2M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, ZJYL ranks #411 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ZJYL compare to SMTI and INGN in the Health Care sector?
▼
Within the Health Care sector (Industrial Specialties), ZJYL carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of 29.2%, and ROIC of —. By comparison, SMTI (Sanara MedTech Inc.) holds a D+ grade (57/100 RQD, P/E 8.1x, ROIC 16.3%, cap $302.4M) and INGN (Inogen Inc) posts a E grade (29/100 RQD, P/E 8.5x, ROIC -27.0%, cap $192.7M). Among the 5-stock peer group, SMTI leads on earnings multiple (8.1x) while SMTI leads on capital efficiency (16.3% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ZJYL?
▼
Per ZJYL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001837821), JIN MEDICAL INTERNATIONAL LTD. (Class A) generated $20.7M in revenue (-12.0% YoY), $1.2M in net income, and -$3.7M in free cash flow against $53.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.85 (-0.57%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-4.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ZJYL)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (47/100 Composite)
🔍 WHY ZJYL SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (21% of score)
FRED Regime × Technicals: 5% of 52W Range • RSI-14 at 61 (BULLISH MOMENTUM)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution6/20 pts (-14 pt drag)
Dilution Drag (+1.64% YoY Shares) & executive Form 4 sales trim 14 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$2.06+1% Next Q
55
Q2 (-2Q)Grade C-$2.08-1.4% Next Q
52
Q3 (-1Q)Grade C-$2.05-9.3% Next Q
50
CurrentGrade D$1.86-5.9% Hist 90D α
47
Trajectory: C (55) → D (47)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ZJYL Turnaround Squeeze
While ZJYL currently carries a cautious 47/100 (D) rating due to Insider Conviction & Share Dilution (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.13) and Max Pain ($1.95) forces dealer call-delta covering toward $8.90.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ZJYL• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ZJYL Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ZJYL Stock dropped -2.10% Today — RQD Quant Desk Flash
JIN MEDICAL INTERNATIONAL LTD. (Class A) (ZJYL) dropped -2.10% to $1.86, trading at 5% of its 52-week range ($1.53 – $8.48). Stretched risk/reward at current multiples (29% profit margin) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 5% of its 52-week range ($1.53 – $8.48) with RSI-14 at 61 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.86 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 29.2% gross margin and $0 annual free cash flow.
Live ZJYL Headlines & Catalysts
MARKET WIREReuters • 3h ago
Nine people dead in Learjet crash in south Florida, officials say - ReutersNine people dead in Learjet crash in south Florida, officials say Reuters
MARKET WIREReuters • 4h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
MARKET WIRECNBC • 6h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 7h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 8h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 9h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 10h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ZJYL)
- ✓Walkthrough of ZJYL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ZJYL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -11.85%▼ DESCENDING CHANNEL
2026-10-30O $1.90H $2.83L $1.83C $1.86VOL 3.66M
RES: $2.80SUP: $0.93SMA50: $2.13SMA200: $2.35
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ZJYL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
40.9%/yr Implied 5Y Growth
vs. -12.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ZJYL today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ZJYL. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ZJYL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ZJYL)
Health Care Rank #411 of 1016
⚔️ SMTI vs ZJYL Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ZJYL vs. SMTI, INGN, AVR, AGPU)
Industry: Industrial Specialties (55 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, JIN MEDICAL INTERNATIONAL LTD. (Class A) (ZJYL) ranks #411 by composite RQD confidence (47/100, grade D) and #520 by equity capitalization ($294.2M). Within this direct 5-issuer industry benchmark cohort, SMTI leads on earnings valuation at 8.1x trailing P/E, while SMTI leads on capital efficiency and profitability with 16.3% ROIC and 92.7% gross margin. SMTI currently holds the highest overall quantitative score in the immediate peer group at 57/100 (D+) compared with ZJYL at 47/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ZJYL
ACTIVE
JIN MEDICAL INTERNATIONAL LTD. (Class A) | D | 47/100 | — | 29.2% | — | -2.10% | $294.2M | Benchmark Subject |
| SMTI Sanara MedTech Inc. | D+ | 57/100 | 8.1x | 92.7% | 16.3% | +0.11% | $302.4M | /smti-vs-zjyl → |
| INGN Inogen Inc | E | 29/100 | 8.5x | 52.2% | -27.0% | +0.14% | $192.7M | /ingn-vs-zjyl → |
| AVR Anteris Technologies Global Corp. | D- | 36/100 | — | 70.3% | -35.0% | +5.25% | $625.9M | /avr-vs-zjyl → |
| AGPU Axe Compute Inc. | D- | 37/100 | — | — | -35.0% | -2.01% | $101.7M | /agpu-vs-zjyl → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001837821In its most recent audited fiscal period (FY2025, filed 2025-09-30), JIN MEDICAL INTERNATIONAL LTD. (Class A) (ZJYL) reported GAAP revenue of $20.7M (-12.0% vs. FY2024 revenue of $23.5M , and +4.4% cumulative change since FY2023) , GAAP net income of $1.2M, operating cash flow of $2.9M, and free cash flow of -$3.7M (-175.6% YoY). On the balance sheet, ZJYL closed FY2025 with $53.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-09-30 | $20.7M | $1.2M | $2.9M | -$3.7M | $53.4M | — |
| FY2024 (FY) | 2024-09-30 | $23.5M | $3.7M | -$1.2M | -$1.4M | — | — |
| FY2023 (FY) | 2023-09-30 | $19.8M | $2.9M | $3.1M | $3.1M | — | — |
3. ZJYL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ZJYL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, JIN MEDICAL INTERNATIONAL LTD. (Class A) (NASDAQ: ZJYL) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $1.86 (-2.10% 1D, market cap $294.2M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, ZJYL ranks #411 in composite RQD confidence.
How does ZJYL compare to SMTI and INGN in the Health Care sector?
Within the Health Care sector (Industrial Specialties), ZJYL carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of 29.2%, and ROIC of —. By comparison, SMTI (Sanara MedTech Inc.) holds a D+ grade (57/100 RQD, P/E 8.1x, ROIC 16.3%, cap $302.4M) and INGN (Inogen Inc) posts a E grade (29/100 RQD, P/E 8.5x, ROIC -27.0%, cap $192.7M). Among the 5-stock peer group, SMTI leads on earnings multiple (8.1x) while SMTI leads on capital efficiency (16.3% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ZJYL?
Per ZJYL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001837821), JIN MEDICAL INTERNATIONAL LTD. (Class A) generated $20.7M in revenue (-12.0% YoY), $1.2M in net income, and -$3.7M in free cash flow against $53.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ZJYL trading relative to its 50-day, 200-day, and 52-week technical levels?
ZJYL last traded at $1.86 (-2.10% on volume of 1,620 shares), positioning the stock -12.68% below its 50-day simple moving average ($2.13) and -20.85% below its 200-day simple moving average ($2.35). Across its 52-week range of $1.53 to $8.48, ZJYL sits at the 4.7% percentile with a 14-day RSI of 61.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($1.63 to $2.09).
ZJYL Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ZJYL stock moving today?
Why ZJYL Stock dropped -2.10% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (29% profit margin) under elevated 10-year interest-rate pressure.